Study Confirms Safety Profile of Baricitinib Dose for Atopic Dermatitis

April 13, 2021

Initial rates of common treatment-emergent adverse events from baricitinib 2 mg appear to remain stable or decrease with prolonged exposure.

Solving Pierced Earring Challenges
The Mainstream Patient: April 12, 2021
COVID-19 Pandemic Provides Glimpse Into Potential Cause of Kawasaki Disease in Children
POLL: Have you seen a rise in aesthetic procedures at your practice since the pandemic began?